scholarly journals Treatment with anti-NAP monoclonal antibody reduces disease severity in murine model of novel angiogenic protein-induced or ovalbumin-induced arthritis

2013 ◽  
Vol 171 (2) ◽  
pp. 155-163 ◽  
Author(s):  
N. B. Nataraj ◽  
J. Krishnamurthy ◽  
B. P. Salimath
Keyword(s):  
Monoclonal Antibody ◽  
Disease Severity ◽  
Murine Model

Anti-interleukin-21 monoclonal antibody reduces disease severity and inflammatory cytokines in a murine model of colitis and psoriasis-like skin inflammation

Cytokine ◽  
2009 ◽  
Vol 48 (1-2) ◽  
pp. 92
Author(s):  
Katherine E. Lewis ◽  
Kristen Bontadelli ◽  
Mark Maurer ◽  
Felecia Wagener ◽  
Kimberly Waggie ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Disease Severity ◽  
Inflammatory Cytokines ◽  
Murine Model ◽  
Skin Inflammation ◽  
Interleukin 21

scholarly journals A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

2020 ◽  
Vol 11 ◽  
Author(s):  
Anna C. Fagre ◽  
John Manhard ◽  
Rachel Adams ◽  
Miles Eckley ◽  
Shijun Zhan ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Disease Severity ◽  
Disease Burden ◽  
Human Monoclonal Antibody ◽  
Receptor Binding Domain ◽  
Yeast Display ◽  
Syrian Hamsters ◽  
Limited Efficacy ◽  
Protein Receptor

The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed. We identified a panel of human monoclonal antibody clones from a yeast display library with specificity to the SARS-CoV-2 spike protein receptor binding domain that neutralized the virus in vitro. Administration of the lead antibody clone to Syrian hamsters challenged with SARS-CoV-2 significantly reduced viral load and histopathology score in the lungs. Moreover, the antibody interrupted monocyte infiltration into the lungs, which may have contributed to the reduction of disease severity by limiting immunopathological exacerbation. The use of this antibody could provide an important therapy for treatment of COVID-19 patients.

scholarly journals Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular Dystrophy

2006 ◽  
Vol 168 (6) ◽  
pp. 1975-1985 ◽  
Author(s):  
Stephanie A. Parsons ◽  
Douglas P. Millay ◽  
Michelle A. Sargent ◽  
Elizabeth M. McNally ◽  
Jeffery D. Molkentin
Keyword(s):  
Muscular Dystrophy ◽  
Disease Severity ◽  
Murine Model ◽  
Limb Girdle Muscular Dystrophy ◽  
Dependent Effect ◽  
Age Dependent

scholarly journals Temporal development of muscle atrophy in murine model of arthritis is related to disease severity

2013 ◽  
Vol 4 (3) ◽  
pp. 231-238 ◽  
Author(s):  
Lidiane I. Filippin ◽  
Vivian N. Teixeira ◽  
Paula R. Viacava ◽  
Priscila S. Lora ◽  
Laura L. Xavier ◽  
...  
Keyword(s):  
Disease Severity ◽  
Muscle Atrophy ◽  
Murine Model ◽  
Temporal Development

scholarly journals Myocardial uptake of antimyosin monoclonal antibody in a murine model of viral myocarditis.

Circulation ◽  
1989 ◽  
Vol 79 (2) ◽  
pp. 400-405 ◽  
Author(s):  
A Matsumori ◽  
T Ohkusa ◽  
Y Matoba ◽  
I Okada ◽  
T Yamada ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Murine Model ◽  
Viral Myocarditis ◽  
Myocardial Uptake
Sign in / Sign up

Export Citation Format

Share Document